Therapeutics News and Research

RSS

Neutrophils dictate whether our immune system will permit or prevent bacterial infections

New research on a bacterium that can survive encounters with specific immune system cells has strengthened scientists' belief that these plentiful white blood cells, known as neutrophils, dictate whether our immune system will permit or prevent bacterial infections.

5 May 2005

Cancer hijacks normal wound-healing processes

Scientists have known for the last decade that a link exists between wound healing and cancer. For instance, in a 1994 experiment at the Lawrence Berkeley National Laboratory, chickens infected with a cancer virus developed tumors in areas of their body that had undergone wounding or scarring, while no tumors developed in infected areas that had not suffered wounding.

5 May 2005

Diabetes researchers look at pizza to find slow and steady insulin delivery wins the race

With its doughy, carbohydrate-dense crust and high fat content, pizza can wreak havoc in people with diabetes. A Penn State Diabetes Center study suggests a slow and steady insulin-dosing pattern may best combat the glucose-raising effects of that common favorite food.

3 May 2005

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

Researchers determine mechanism of action of chemotherapy drug motexafin gadolinium

The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.

1 May 2005

Maxim Pharmaceuticals issued patent for method of identifying therapeutically effective immunosupressive agents

Maxim Pharmaceuticals have announced the United States Patent and Trademark Office issued U.S. patent number 6,828,091 B2, entitled "Method of Identifying Immunosuppressive Agents."

23 Apr 2005

Smad7 protein levels may predict prostate cancer therapy response

Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).

23 Apr 2005

Scientists weaponize an antibody to deliver continuous attacks on cancer cells

In a recent study published in Molecular Cancer Therapeutics, researchers at the Weizmann Institute of Science paired the active ingredient of a garden remedy with advanced bio-technology to deliver a powerful punch against cancer. The cancer killing effectiveness lies in their technique of arming a cancer-targeting antibody with the destructive potential of the dietary molecule otherwise known as "allicin."

22 Apr 2005

New strategy to identify differences between non-metastatic and highly metastatic breast cancer cells

Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.

22 Apr 2005

Genes influence how heart failure patients respond to drugs

Genes dictate the color of our hair and eyes. They factor into whether we get cancer or heart disease. And, scientists increasingly recognize, they also ensure some patients will benefit from a prescription drug, while others develop adverse reactions or simply fail to respond at all.

21 Apr 2005

Fast Track designation for Terlipressin in type 1 hepatorenal syndrome

Protein Design Labs, Inc. and privately held Orphan Therapeutics, LLC today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).

20 Apr 2005

Halozyme Therapeutics receives FDA clearance for Cumulase

Halozyme Therapeutics has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Cumulase for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The active pharmaceutical ingredient in Cumulase is the first and only recombinant human hyaluronidase approved in the United States for cumulus removal in the IVF process.

20 Apr 2005

Compound derived from cottonseed oil could help improve the effectiveness of chemotherapy at treating head and neck cancer

The findings, which will be presented Tuesday, April 19, at the American Association for Cancer Research annual meeting, could lead to a treatment that provides an effective option to surgically removing the cancer, helping patients preserve vital organs involved in speech and swallowing.

19 Apr 2005

Researcher grows new insulin-secreting beta cells from pancreatic tissue

JDRF-funded researchers in Canada and Massachusetts have stimulated the birth of new insulin-secreting beta cells by treating human islets with a mixture of two naturally occurring peptides: epidermal growth factor (EGF) and gastrin.

12 Apr 2005

Groundbreaking results for the potential treatment of Huntington's Disease

Sirna Therapeutics announced today that its collaborator at the University of Iowa, Dr. Beverly Davidson, published groundbreaking results for the potential treatment of Huntington's Disease (HD).

12 Apr 2005

Significant progress in pSivida BioSilicon drug delivery evaluation

Global nanotechnology company pSivida Limited has announced that its evaluation of selected compounds from an undisclosed top five global pharmaceutical company has progressed successfully.

11 Apr 2005

Genomics and proteomics to increase the efficiency of drug discovery and development

While the United Sates is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to deploy genomics and proteomics as vital tools in drug discovery and development.

5 Apr 2005

DNA repair kit announced by scientists

A study by scientists at Sangamo BioSciences, Inc. has demonstrated the use of the Company's zinc finger DNA-binding protein (ZFP) technology to achieve highly efficient, permanent correction of a disease-causing gene in primary human cells.

5 Apr 2005

EvoGenix expands capabilities through US acquisition

EvoGenix and Absalus own complementary technologies which, when combined, are capable of streamlining the identification of new antibody drug candidates and improving the development of safe and effective human therapeutic antibodies.

4 Apr 2005

Statins, other cholesterol-depleting agents, may disrupt hypertension from developing

Cholesterol-lowering agents, such as the widely-prescribed statin drugs, and cholesterol-blocking agents may prove to be “novel therapeutic agents to modify cellular calcium that contributes to the development of pulmonary hypertension,” according Hemal H. Patel who lead a multidisciplinary team of researchers at the University of California, San Diego (UCSD).

3 Apr 2005